Fig. 6.
![Fig. 6. The influence of increased neutrophil counts during G-CSF therapy on ADCC against SK-BR–3 breast cancer cells was investigated in the presence of 0.4 μg/mL of BsAb (A77 × 520C9) directed to HER-2/neu and FcαRI. As effector cell source, 50 μL whole blood from patients before G-CSF (before), after 3 and 7 days of G-CSF (3 days and 7 days, respectively), or after G-CSF treatment (after) were compared. During G-CSF therapy, significant enhancement of BsAb-mediated ADCC was paralleled by significant increases in neutrophil numbers (P < .05, indicated by an asterisk [*]). Results from three experiments are presented as mean ± SEM of % specific lysis. (○), No antibody; (▴), (A77 × 520C9); (•), PMN count.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/90/11/10.1182_blood.v90.11.4485/3/bl_0031f6.jpeg?Expires=1735512864&Signature=VIWTQwN9Rinki3KZehkOyiMbhwD0glu5wEmvPo2QleeGG9qyYB3XoSH02E3MGCdEKlMKxPD7DisCyRp2WRdFqKuwXv-TXTgeZZcpgPeNoyHsXr2K0VEnNre9DnI7JPM2scbAtEaRI5XR4FVZlWAuavzXK0jGsTLZ1py~kpqgKJb6cvXaw-O7dmHnOG8FkQRBRbjDv9LhmyUBh1329O3doA2N7QmXjOXGmATsA5yWpvpxfuIJXm6F49Jm9A8vetVkenifsjT8XC1j-BXpJZEAoPExqO5gMhInCTOoMCy1hBr~W~JQladbqCyy0enYTKAJxgcgjtsLTUn~0GbmiT3qcQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The influence of increased neutrophil counts during G-CSF therapy on ADCC against SK-BR–3 breast cancer cells was investigated in the presence of 0.4 μg/mL of BsAb (A77 × 520C9) directed to HER-2/neu and FcαRI. As effector cell source, 50 μL whole blood from patients before G-CSF (before), after 3 and 7 days of G-CSF (3 days and 7 days, respectively), or after G-CSF treatment (after) were compared. During G-CSF therapy, significant enhancement of BsAb-mediated ADCC was paralleled by significant increases in neutrophil numbers (P < .05, indicated by an asterisk [*]). Results from three experiments are presented as mean ± SEM of % specific lysis. (○), No antibody; (▴), (A77 × 520C9); (•), PMN count.
